DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Price, Quote, News and Overview
NASDAQ:DVAX - Nasdaq - US2681582019 - Common Stock - Currency: USD
DVAX Quote, Performance and Key Statistics
10.82
-0.08 (-0.73%)
The current stock price of DVAX is 10.82 USD. In the past month the price decreased by -21.14%. In the past year, price decreased by -3.48%.
DVAX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About DVAX
Company Profile
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 405 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. The company also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. The company is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Company Info
DYNAVAX TECHNOLOGIES CORP
2100 Powell Street, Suite 720
Emeryville CALIFORNIA 94608 US
CEO: Ryan Spencer
Employees: 408
Company Website: https://www.dynavax.com/
Investor Relations: https://investors.dynavax.com
Phone: 15108485100
DYNAVAX TECHNOLOGIES CORP / DVAX FAQ
What is the stock price of DYNAVAX TECHNOLOGIES CORP today?
The current stock price of DVAX is 10.82 USD. The price decreased by -0.73% in the last trading session.
What is the ticker symbol for DYNAVAX TECHNOLOGIES CORP stock?
The exchange symbol of DYNAVAX TECHNOLOGIES CORP is DVAX and it is listed on the Nasdaq exchange.
On which exchange is DVAX stock listed?
DVAX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DYNAVAX TECHNOLOGIES CORP stock?
12 analysts have analysed DVAX and the average price target is 24.89 USD. This implies a price increase of 130.02% is expected in the next year compared to the current price of 10.82. Check the DYNAVAX TECHNOLOGIES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DYNAVAX TECHNOLOGIES CORP worth?
DYNAVAX TECHNOLOGIES CORP (DVAX) has a market capitalization of 1.34B USD. This makes DVAX a Small Cap stock.
How many employees does DYNAVAX TECHNOLOGIES CORP have?
DYNAVAX TECHNOLOGIES CORP (DVAX) currently has 408 employees.
What are the support and resistance levels for DYNAVAX TECHNOLOGIES CORP (DVAX) stock?
DYNAVAX TECHNOLOGIES CORP (DVAX) has a support level at 10.25 and a resistance level at 10.83. Check the full technical report for a detailed analysis of DVAX support and resistance levels.
Is DYNAVAX TECHNOLOGIES CORP (DVAX) expected to grow?
The Revenue of DYNAVAX TECHNOLOGIES CORP (DVAX) is expected to grow by 17.43% in the next year. Check the estimates tab for more information on the DVAX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DYNAVAX TECHNOLOGIES CORP (DVAX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DVAX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DVAX, evaluating the profitability, health, valuation and growth aspects
- DYNAVAX TECHNOLOGIES CORP (DVAX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DYNAVAX TECHNOLOGIES CORP (DVAX) Sales and EPS estimates to see what analysts future expectations are.
- DYNAVAX TECHNOLOGIES CORP (DVAX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DYNAVAX TECHNOLOGIES CORP (DVAX) Insider and Institutional Ownership to learn about the owners and their transactions.
- DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Chart to make your own analysis
- DYNAVAX TECHNOLOGIES CORP (DVAX) Latest news and press-releases to stay up to date.
Does DYNAVAX TECHNOLOGIES CORP (DVAX) stock pay dividends?
DVAX does not pay a dividend.
When does DYNAVAX TECHNOLOGIES CORP (DVAX) report earnings?
DYNAVAX TECHNOLOGIES CORP (DVAX) will report earnings on 2025-05-01, after the market close.
What is the Price/Earnings (PE) ratio of DYNAVAX TECHNOLOGIES CORP (DVAX)?
The PE ratio for DYNAVAX TECHNOLOGIES CORP (DVAX) is 60.11. This is based on the reported non-GAAP earnings per share of 0.18 and the current share price of 10.82 USD. Check the full fundamental report for a full analysis of the valuation metrics for DVAX.
What is the Short Interest ratio of DYNAVAX TECHNOLOGIES CORP (DVAX) stock?
The outstanding short interest for DYNAVAX TECHNOLOGIES CORP (DVAX) is 15.34% of its float. Check the ownership tab for more information on the DVAX short interest.
DVAX Technical Analysis
DVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DVAX. DVAX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
DVAX Financial Highlights
Over the last trailing twelve months DVAX reported a non-GAAP Earnings per Share(EPS) of 0.18. The EPS increased by 400% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.85% | ||
| ROA | 2.77% | ||
| ROE | 4.58% | ||
| Debt/Equity | 0.38 |
DVAX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to DVAX. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 91.08% and a revenue growth 17.43% for DVAX